News & Media

At Ichnos Glenmark Innovation, we’re working to make real progress in science and medicine.
Explore our recent publications to discover how we’re shifting medicine forward.

DateTitleType
13 Feb 2025February 2025 UpdateCorporate Updatearrow_green
09 Dec 2024Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple MyelomaPress Releasearrow_green
19 Nov 2024Corporate Presentation November 2024 UpdateCorporate Updatearrow_green
13 Nov 2024November 2024 UpdateCorporate Updatearrow_green
05 Nov 2024Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual MeetingPress Releasearrow_green
30 Sept 2024IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast CancerPress Releasearrow_green
11 Sept 2024IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple MyelomaPress Releasearrow_green
13 Aug 2024August 2024 UpdateCorporate Updatearrow_green
23 May 2024May 2024 UpdateCorporate Updatearrow_green
30 April 2024Corporate Presentation April 2024Corporate Updatearrow_green
07 April 2024IGI presents preclinical data for ISB 2001 at AACR 2024Press Releasearrow_green
08 March 2024Ichnos Glenmark Innovation reports the publication in Nature Communications of the preclinical development of ISB 1442 bispecific antibody for Treatment of Relapsed/Refractory Multiple MyelomaPress Releasearrow_green
13 February 2024February 2024 UpdateCorporate Updatearrow_green
30 Jan 2024Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - ‘Ichnos Glenmark Innovation’Press Releasearrow_green
12 Dec 2023Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual MeetingsPress Releasearrow_green
06 Dec 2023Ichnos Sciences Appoints President and CEO Cyril Konto as Executive Director to the BoardCorporate Updatearrow_green
09 Nov 2023November 2023 Update
Corporate Updatearrow_green
09 Nov 2023Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual MeetingPress Releasearrow_green
02 Nov 2023Ichnos Sciences Announces Initiation of First-In-Human Clinical Trial for ISB 2001
Press Releasearrow_green
11 Oct 2023Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria TherapeuticsPress Releasearrow_green
10 Aug 2023August 2003 Update
Corporate Updatearrow_green
07 Jul 2023Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001
Press Releasearrow_green
18 May 2023May 2023 Update
Corporate Updatearrow_green
20 Mar 2023Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442
Press Releasearrow_green
09 Feb 2023February 2023 Update
Corporate Updatearrow_green
12 Dec 2022Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting
Press Releasearrow_green
10 Nov 2022November 2022 Update
Corporate Updatearrow_green
03 Nov 2022Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting
Press Releasearrow_green
09 Aug 2022August 2022 Update
Corporate Updatearrow_green
08 Jun 2022Webcast: Ichnos Sciences Presentation at the 2022 Jefferies Healthcare Conference
Eventarrow_green
26 May 2022August 2022 Update
Corporate Updatearrow_green
12 May 2022Pharma Boardroom: Cyril Konto, President & CEO – Ichnos SciencesMediaarrow_green
27 April 2022Law360: Ichnos Sciences’ New GC On Carving Out ‘Creative Time'Mediaarrow_green
12 April 2022Genetic Engineering & Biotechnology News: Multi-Specific Ab Analytical Strategies
Mediaarrow_green
23 Mar 2022Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting
Press Releasearrow_green
18 Mar 2022Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference
Press Releasearrow_green
10 Feb 2022February 2022 Update
Corporate Updatearrow_green
16 Dec 2021
Scrip: Ichnos Gets Going with Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
Mediaarrow_green
14 Dec 2021Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody
Press Releasearrow_green
11 Dec 2021ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma
Data Presentationarrow_green
11 Dec 2021Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting
Press Releasearrow_green
11 Nov 2021November 2021 Update
Corporate Updatearrow_green
12 Aug 2021August 2021 Update
Corporate Updatearrow_green
06 Aug 2021Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma
Press Releasearrow_green
04 Jun 2021Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting
Press Releasearrow_green
27 May 2021May 2021 Update
Corporate Updatearrow_green